Outlook Therapeutics Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Bob Jahr

Chief executive officer

US$1.7m

Total compensation

CEO salary percentage	8.61%
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	3.4yrs
Board average tenure	7.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Bob Jahr's remuneration changed compared to Outlook Therapeutics's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2026	n/a	n/a	-US$61m
Dec 31 2025	n/a	n/a	-US$103m
Sep 30 2025	US$2m	US$150k	-US$62m

Compensation vs Market: Bob's total compensation ($USD1.74M) is above average for companies of similar size in the German market ($USD440.72K).

Compensation vs Earnings: Insufficient data to compare Bob's compensation with company performance.

CEO

Bob Jahr (53 yo)

less than a year

Tenure

US$1,741,757

Compensation

Mr. Robert Charles Jahr, also known as Bob, is President, CEO & Director of Outlook Therapeutics, Inc. from July 1, 2025. From September 2018 to April 2020, he served as Vice President Head of US Payer Val...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Robert Jahr	President	less than a year	US$1.74m	no data
Lawrence Kenyon	EVP, CFO	10.8yrs	US$476.17k	0.0049% € 3.7k
Joel Prieve	Senior Vice President of Licensing and M&A	4.3yrs	no data	no data
Surendra Sharma	Senior Vice President of Medical Affairs	3.4yrs	no data	no data
Jennifer Kissner	Senior Vice President of Clinical Development & Regulatory Affairs	no data	no data	no data
Jedd Comiskey	Senior VP - Head of Europe	2.6yrs	no data	no data

3.4yrs

Average Tenure

Experienced Management: 41O's management team is considered experienced (3.4 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Robert Jahr	President	less than a year	US$1.74m	no data
Lawrence Kenyon	EVP, CFO	7.8yrs	US$476.17k	0.0049% € 3.7k
Kurt Hilzinger	Independent Director	10.5yrs	US$842.00k	0.35% € 265.0k
Ralph Thurman	Lead Independent Director	8.2yrs	US$836.50k	0.0046% € 3.5k
Julian Gangolli	Independent Non-Employee Director	6.2yrs	US$690.50k	0% € 0
Gerd Auffarth	Independent Non-Employee Director	6.2yrs	US$458.00k	0% € 0
Faisal Sukhtian	Independent Chairman of the Board	8.8yrs	US$1.00m	0.10% € 78.5k
Yezan Haddadin	Independent Director	8.7yrs	US$974.00k	0.055% € 41.4k
Andong Huang	Independent Director	6yrs	US$425.00k	0% € 0

7.8yrs

Average Tenure

60yo

Average Age

Experienced Board: 41O's board of directors are considered experienced (7.8 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/06/09 11:08
End of Day Share Price	2026/06/09 00:00
Earnings	2026/03/31
Annual Earnings	2025/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Outlook Therapeutics, Inc. is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Edward Woo	Ascendiant Capital Markets LLC
Brian Kemp Dolliver	Brookline Capital Markets
Kumaraguru Raja	Brookline Capital Markets

Outlook Therapeutics Management

Management criteria checks 2/4

Key information

Recent management updates

Independent Director recently bought €152k worth of stock

Insufficient new directors

Outlook Therapeutics, Inc. Announces Resignation of Dr. Julia Haller from the Board and Member of the Nominating and Corporate Governance Committee, Effective March 11, 2026

Outlook Therapeutics, Inc., Annual General Meeting, Mar 10, 2026

Insufficient new directors

Outlook Therapeutics, Inc. Announces Chief Executive Officer Changes

Recent updates

Independent Director recently bought €152k worth of stock

Outlook Therapeutics, Inc. Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)

Outlook Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $5 million.

Outlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process For ONS-5010/LYTENAVA (Bevacizumab-Vikg) And Plans To Resubmit BLA To FDA In June 2026

Insufficient new directors

Outlook Therapeutics, Inc. has completed a Follow-on Equity Offering.

Outlook Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $5 million.

Outlook Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $5 million.

Outlook Therapeutics Inc. Announces FDA Accepts Formal Dispute Resolution Request for ONS-5010/LYTENAVA (Bevacizumab-Vikg)

Outlook Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $5 million.

Outlook Therapeutics, Inc. has filed a Follow-on Equity Offering.

Outlook Therapeutics, Inc. announced that it has received $18.36 million in funding from Atlas Sciences, LLC

Outlook Therapeutics, Inc. Announces Resignation of Dr. Julia Haller from the Board and Member of the Nominating and Corporate Governance Committee, Effective March 11, 2026

Outlook Therapeutics Provides Update Following Type A Meeting With FDA Regarding ONS-5010/LYTENAVA (Bevacizumab-Vikg)

Outlook Therapeutics, Inc. Receives Notice of Potential Delisting Due to Low Stock Price on Nasdaq

Outlook Therapeutics, Inc. Submits Type A Meeting Request to FDA Following Complete Response Letter

Outlook Therapeutics, Inc., Annual General Meeting, Mar 10, 2026

Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of Ons-5010/Lytenava™ (Bevacizumab-Vikg) for the Treatment of Wet Amd

Insufficient new directors

Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics, Inc. Re-Submits Biologics License Application for ONS-5010

Outlook Therapeutics, Inc. Announces Type A Meeting with the U.S. Food and Drug Administration Resubmission for Ons-5010

Outlook Therapeutics, Inc. Provides Regulatory Update on U.S. Food and Drug Administration Review of Ons-5010/Lytenava™? (Bevacizumab-Vikg) for the Treatment of Wet Amd

Outlook Therapeutics, Inc. Announces Chief Executive Officer Changes

Outlook Therapeutics, Inc.(NasdaqCM:OTLK) dropped from Russell 2000 Index

Outlook Therapeutics®? Announces Smc Recommendation of Lytenava™ (Bevacizumab Grapa) for the Treatment of Wet Amd

Outlook Therapeutics, Inc. Announces Commercial Launch of LYTENAVA (bevacizumab G gamma) in Germany and the UK for the Treatment of Wet AMD

Outlook Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $13 million.

Outlook Therapeutics, Inc. has filed a Follow-on Equity Offering.

Outlook Therapeutics, Inc. Announces U.S. Food and Drug Administration Resubmission of ONS-5010 Biologics License Application

Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

Outlook Therapeutics, Inc., Annual General Meeting, Mar 11, 2025

Outlook Therapeutics, Inc. Appoints Faisal G. Sukhtian as Chairman of the Board of Directors

Outlook Therapeutics Announces Presentation of Efficacy and Safety Results from Norse Eight Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD

Outlook Therapeutics, Inc. Announces Complete Twelve Week Efficacy and Safety Results of Northeast EIGHT Clinical Trial

Outlook Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt

Outlook Therapeutics, Inc. Streamlines Operations

Outlook Therapeutics, Inc. Announces Chief Executive Officer Changes

Outlook Therapeutics, Inc Announces Resignation of Russell Trenary as President

Outlook Therapeutics, Inc. Announces Preliminary Topline Results of Norse Eight Clinical Trial

Forecast to breakeven in 2027

Outlook Therapeutics Announces Completion of Enrollment in NORSE EIGHT Clinical Trial

New major risk - Financial position

Outlook Therapeutics, Inc. to Report Q3, 2024 Results on Aug 14, 2024

Insufficient new directors

Outlook Therapeutics, Inc. Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics, Inc. to Report Q2, 2024 Results on May 16, 2024

Outlook Therapeutics, Inc. announced that it has received $5.000002 million in funding from Syntone Ventures LLC

Outlook Therapeutics Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD

New major risk - Shareholder dilution

Outlook Therapeutics, Inc. announced that it has received $59.999961 million in funding from a group of investors

Outlook Therapeutics Announces Effective Date for 1-For-20 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement

No longer forecast to breakeven

Outlook Therapeutics, Inc., Annual General Meeting, Mar 07, 2024

Outlook Therapeutics, Inc. Doses First Subject in Norse Eight

Outlook Therapeutics Receives FDA Agreement under Special Protocol Assessment for 90 Day Non-Inferiority Study, NORSE EIGHT

Outlook Therapeutics, Inc. announced that it expects to receive $65 million in funding from a group of investors

Forecast breakeven date pushed back to 2026

Outlook Therapeutics, Inc. Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ONS-5010

Outlook Therapeutics, Inc. Announces Strategic Organizational Realignment

Outlook Therapeutics, Inc. Appoints Jedd Comiskey as Senior VP – Head of Europe

Pomerantz Law Firm Announces the Filing of A Class Action Against Outlook Therapeutics, Inc. and Certain Officers

Outlook Therapeutics, Inc. Provides Update on Type A Meetings with FDA

Outlook Therapeutics Receives Non-Compliance Notice from Nasdaq

Outlook Therapeutics, Inc. Provides Regulatory Update on FDA Review of ONS-5010 / LYTENAVA (bevacizumab-vikg) for the Treatment of Wet AMD

New major risk - Negative shareholders equity

Outlook Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $16.927904 million.

Forecast breakeven date moved forward to 2024

High number of new directors